ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

TOPOSAR
Prostate and other male cancers
Respiratory and thoracic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

TOPOSAR Rx

Generic Name and Formulations:
Etoposide 20mg/mL; soln for IV infusion; contains dehydrated alcohol 33.2%, polysorbate 80.

Company:
Teva Pharmaceuticals

Therapeutic Use:

Indications for TOPOSAR:

Refractory testicular tumors after appropriate radiation, surgery, and other chemotherapy.

Adult:

Give by slow IV infusion over 30–60mins. Range 50–100mg/m2 per day on days 1 through 5 to 100mg/m2 per day on days 1, 3, and 5. Repeat course every 3 to 4 weeks after recovery from any toxicity. Renal impairment (CrCl 15–50mL/min): reduce dose to 75%; (CrCl <15mL/min): see literature. Consider dose reduction with existing myelosuppression due to previous radiation or chemotherapy.

Children:

Not recommended.

Warnings/Precautions:

Monitor for myelosuppression; obtain CBCs with differential, platelets, hemoglobin at baseline, prior to each subsequent dose, during and after therapy. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Renal impairment. Hypoalbuminemia. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Interactions:

Potentiated by cyclosporine. Additive toxicity with radiation, other cytotoxic therapies.

Pharmacological Class:

Topoisomerase inhibitor.

Adverse Reactions:

Hypersensitivity/infusion reactions (eg, fever/chills, hypotension, bronchospasm), GI upset, anorexia, mucositis, myelosuppression (esp neutropenia, thrombocytopenia; may be fatal), alopecia, fever, infections, peripheral neurotoxicity; rare: acute leukemia; others.

How Supplied:

Multi-dose vials (5mL, 25mL, 50mL)—1

Indications for TOPOSAR:

First-line treatment of small cell lung cancer.

Adult:

Give by slow IV infusion over 30–60mins. Range 35mg/m2 per day for 4 days to 50mg/m2 per day for 5 days. Repeat course every 3 to 4 weeks after recovery from any toxicity. Renal impairment (CrCl 15–50mL/min): reduce dose to 75%; (CrCl <15mL/min): see literature. Consider dose reduction with existing myelosuppression due to previous radiation or chemotherapy.

Children:

Not recommended.

Warnings/Precautions:

Monitor for myelosuppression; obtain CBCs with differential, platelets, hemoglobin at baseline, prior to each subsequent dose, during and after therapy. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Renal impairment. Hypoalbuminemia. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Interactions:

Potentiated by cyclosporine. Additive toxicity with radiation, other cytotoxic therapies.

Pharmacological Class:

Topoisomerase inhibitor.

Adverse Reactions:

Hypersensitivity/infusion reactions (eg, fever/chills, hypotension, bronchospasm), GI upset, anorexia, mucositis, myelosuppression (esp neutropenia, thrombocytopenia; may be fatal), alopecia, fever, infections, peripheral neurotoxicity; rare: acute leukemia; others.

How Supplied:

Multi-dose vials (5mL, 25mL, 50mL)—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs